Camurus Expands Collaboration with Eli Lilly to Include Amylin Receptor Agonists

Camurus Enhances Partnership with Eli Lilly

In an important development for both companies, Camurus AB (NASDAQ STO: CAMX), a biopharmaceutical company based in Lund, Sweden, has revealed its expansion of collaboration with Eli Lilly and Company. Announced on June 1, 2026, this collaboration now includes the incorporation of amylin receptor agonists into their existing agreement, which initially commenced in June 2025.

What This Means for the Collaboration

With this new addition, Eli Lilly has secured exclusive global rights to incorporate Camurus' proprietary FluidCrystal® technology into the development and commercial validation of long-acting cardiometabolic medications. This expansion now encompasses up to four unique drug compounds across three distinct classes. These include dual GLP-1 and GIP receptor agonists, triple agonists targeting GLP-1, GIP, and glucagon receptor agonists, as well as the newly introduced amylin receptor agonists.

Fredrik Tiberg, President and CEO of Camurus, expressed enthusiasm about this development, stating: "Lilly's decision to exercise the option validates our technology, broadens our partnership and extends FluidCrystal into the expanding field of amylin therapeutics." Tiberg's comments illustrate the optimism felt at Camurus regarding the evolution of this collaboration and its potential to create significant advancements in therapeutic landscapes.

Financial Implications of the Agreement

Under the terms of the collaboration agreement, Camurus stands to gain substantial financial benefits, with the potential to receive up to $290 million in upfront and milestone payments associated with development and regulatory processes. Additionally, the company could earn up to $580 million tied to sales-based milestones, alongside tiered royalties classified as mid-single digits based on product sales. The option's exercise immediately triggers a payment of $5 million to Camurus while maintaining the same milestone payment structure and royalty levels applicable to the other compounds involved in the collaboration.

FluidCrystal® Technology: A Game Changer

FluidCrystal technology, developed by Camurus, is engineered for sustained drug delivery, providing therapeutic levels over extended periods with a single injection method, whether via a prefilled syringe or an autoinjector pen. Upon interaction with bodily fluids, this lipid-based solution converts into a gel-like substance that effectively encapsulates the active ingredient. This innovative approach allows for a gradual release of the medication as the gel degrades, enhancing patient experiences and outcomes in treatment.

This technology has garnered commercial and regulatory validation, with approvals and utilization in Europe, the U.S., and Australia.

Camurus: Commitment to Innovation

Camurus is dedicated to pioneering innovative long-acting medicines aimed at improving the quality of life for patients dealing with severe and chronic health conditions. The company’s research and development (R&D) initiatives focus on creating products with leading-edge potential, leveraging their FluidCrystal® technology alongside extensive scientific expertise. Their R&D pipeline highlights active developments for treatments targeting dependence, pain management, cancer therapies, and various endocrine disorders. Camurus operates not just in Sweden, but also across Europe, the United States, and Australia, maintaining headquarters in Lund, within Sweden. Investors can find Camurus on the Nasdaq Stockholm under the ticker symbol CAMX.

In conclusion, the expansion of partnership between Camurus and Eli Lilly signifies a pivotal moment in the evolution of advanced therapeutics, potentially enhancing the treatment landscape within the cardiometabolic domain, and paving the way for innovative solutions for patients worldwide.

For further information, attendees of upcoming investor conferences and healthcare forums are encouraged to follow updates from Camurus to learn about their developments ahead of the market.